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Summary.-The leucocyte adherence inhibition (LAI) test, previously described for
the detection of cell mediated immunity and serum blocking factors associated with
murine tumours, has now been adapted for use with human cancer patients. Blood
leucocytes from these patients, mixed in vitro with antigenic extracts of tumours of
the same type, had their normal adherence to glass surfaces diminished. This
inhibition was reversed (blocked) by the addition of the patients' own sera. Both
LAI and blocking were tumour-type specific, but showed complete cross-reactivity
within each type of tumour (melanoma, colon carcinoma, mammary carcinoma).
The LAI test could be of great value in diagnosis and evaluation of treatment,
since it seems to reproduce consistently the findings made by more elaborate
techniques but has the advantage of being simple, rapid and inexpensive.
CELLULAR (lymphocyte mediated) and
humoral (antibody mediated) immune
responses in cancer have been extensively
studiedand their manifestations character-
ized by various in vitro techniques. In
recent years, specific cell mediated im-
munity (CMI) has been demonstrated in
human patients towards antigens of their
own tumours, by lymphocyte cytotoxicity
(Hellstr6m et al., 1968, 197la), lymphocyte
transformation (Vanky et al., 1971) and
macrophage migration inhibition (Ander-
sen, Bendixen and Schi0dt, 1969). Cir-
culating anti-tumour antibodies have been
detected by several methods, notably
immunofluorescence (Lewis et al., 1969)
and complement-dependent cytotoxicity
(Hellstrom et al., 1968); antibody-like
blocking factors (BF), which interfere with
CMI, are now well known in association
with tumour growth (Hellstrom et al.,
1971b, 1973; Halliday, 1972; Hellstrom
and Hellstrom, 1973a, b).
A rapid, simple variation of the
macrophage migration test, called leuco-
cyte adherence inhibition (LAI) and
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characterized in detail with experimental
murine tumours (Halliday and Miller,
1972; Halliday, Maluish and Miller, 1973),
appears to have many advantages for the
immunological investigation of human
cancer.
MATERIALS AND METHODS
Collection of leucocytes.-Blood was ob-
tained in 15 ml quantities by venepuncture
and mixed gently with approximately 500
units of heparin in 25 ml glass bottles. The
bottles were placed in an incubator at 37TC
for 1 hour to allow the erythrocytes to settle,
then the leucocyte-rich plasma was removed
by pipette. After centrifugation of the
plasma at 200q for 5 min, the cell pellets
were treated briefly with 1-5 ml of distilled
water to lyse the remaining erythrocytes.
The leucocytes were then restored quickly to
a more favourable medium by the addition
of 3-5 ml of Eagle's basal medium (Common-
wealth Serum Laboratories) containing 10%
foetal calf serum and 0-28 mg/ml of sodium
bicarbonate (Halliday et al., 1973). This
medium was used throughout the procedure.
The cells were counted, centrifuged again andW. J. HALLIDAY, A. MALUISH AND W. H. ISBISTER
resuspended in medium to a concentration
of 2 x 107/ml.
Serum.-A further 5 ml of blood was
allowed to coagulate and the serum was
removed and stored, if necessary, at -20°C.
Sera were not heat treated, but were arbi-
trarily diluted 1: 1 with medium before use
(final concentration in test 1: 8).
Tumour extracts (antigens).-Aqueous ex-
tracts were prepared byhomogenizing tumour
tissue in 4 volumes ofcold phosphate buffered
saline. The homogenates were centrifuged,
first at 1000g for 30 min to clarify, then at
20,000g for 30 min. The resulting clear
supernatants were stored at -20°C in small
aliquots. One extract of a colonic carcinoma
was made with perchloric acid (Krupey,
Gold and Freedman, 1968), followed by
dialysis against distilled water. None of the
tumours were autochthonous with respect
to the patients studied inthisseries. Extracts
were diluted 1: 5 with medium before use
(final concentration in test 1: 20).
The LAI test.-Equal volumes (0'05 ml)
of leucocyte suspension (106 cells), diluted
tumour antigen and diluted serum (when
required) were mixed, with the addition of
medium, to make the final volume 0-2 ml.
Duplicate mixtures were made of each
combination and were randomized and coded
by another person. The mixtures were
incubated at 37°C for 30 min in small capped
plastic tubes (10 mm diameter), and vigor-
ously shaken every 5 min.
After preliminary incubation, the mix-
tures were introduced into haemacytometer
chambers. The haemacytometers (Levy
counting chambers with improved Neubauer
ruling, Arthur H. Thomas Co., Philadelphia)
must be of a type which allows the coverslip
to be floated off (see below). One haema-
cytometer (with 2 sides or chambers) was used
for each tube and when filled was incubated
in a humid atmosphere at 37°C for approxi-
mately 60 min. Then the nucleated cells
were counted microscopically at x400 magni-
fication in a predetermined pattern ofsquares.
Eight squares (each 0-2 mm x 0-2 mm) were
counted on each side, or 16 squares for each
tube. Haemacytometers were returned to a
humid atmosphere at room temperature after
counting, to prevent drying.
After all the haemacytometers had been
counted the coverslips were removed by
flotation. Each slide was held a few degrees
from horizontal and slowly lowered into a
petri dish of Hanks' solution at room tem-
perature, so that the liquid filled the channels
under the coverslip. Further immersion left
the coverslip floating, and it could be picked
up with forceps. The slide was then held by
one end and slowly immersed in a beaker of
Hanks' solution, withdrawn, reversed and
again immersed and withdrawn. Finally, a
drop of Hanks' solution was placed gently on
each side and a clean coverslip put in place
with forceps.
The adherent cells remaining on the slide
were counted in the same squares as examined
previously. Percent adherent cells for each
square (16 determinations for each replicate
ofeach mixture) were then calculated.
Calculations.-The mean percentage of
adherent cells and standard error ofthe mean
(s.e. mean) were calculated for each mixture
(treating each square as a separate determi-
nation) and the statistical significance of the
difference between means was determined by
the t-test.
RESULTS
When leucocytes from normal volun-
teers or patients with cancer were allowed
to settle on a glass surface in a haema-
cytometer, approximately 45-70% of the
cells adhered to the surface and withstood
a gentle washing procedure. The per-
centage adherence was reproducible for a
given donor on any one day and was
significantly diminished by lymphocyte-
antigen interaction, as described below.
A necessary preliminary to the use of
tumour extracts as antigens was the
investigation of their toxicity for normal
cells in the LAI test. If an extract
exhibited such nonspecific activity it was
discarded. All of the melanoma extracts
(M1-M4) and breast carcinoma extracts
(Bl and B2) were non-toxic. Two aqueous
extracts of colonic carcinoma (Cl and C2)
were toxic (possibly because of contami-
nating enteric bacteria or their products)
but a perchloric acid extract (C3) was not
inhibitory to normal leucocyte adherence.
Antigenic extracts from 3 types of
tumour were specifically reactive with
patients' leucocytes. Table I shows that
leucocytes were active in 2 patients with
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TABLE I.-Activity ofAntigens and Appro-
priate Patients' Leucocytes in LAI
Leucocytes
Melanoma (A.C.)
Melanoma (A.C.)
Melanoma (A.C.)
Melanoma (D.Z.)
Melanoma (D.Z.)
Carcinoma of colon (J.T.)
Carcinoma of colon (J.T.)
Carcinoma of breast (O.K.)
Carcinoma of breast (O.K.)
Carcinoma of breast (O.K.)
Carcinoma of breast (O.K.)
Carcinoma of breast (O.K.)
% Adherence
Antigen (Mean ± s.e.)
65-1 2-8
Ml 37-2 ± 2-4t
M2 40-0 2-3t
69-0 2 2-3
Ml 49-1 2-6t
Ml 67-2 2-9
C3 32-8 ± 1-8t
68-8 ± 22
M3 73.9 ± 2-2*
M4 73-6± 1-8*
BL 37-6 2-3t
B2 34-7 ± 2-3t
* Not inhibited.
t Significantly inhibited (P < 0-001).'
melanoma (against 2 different melanoma
extracts, compared with no antigen), in
one patientwithcolonic carcinoma (against
colonic carcinoma antigen, compared with
melanoma) and in one patient with
carcinoma of breast (against 2 breast
carcinoma extracts, compared with no
antigen and with 2 other melanoma
extracts).
Serum from the above patients, or
from other appropriate patients or normal
controls, was next tested for blocking
activity, that is, the specific ability to
prevent the LAI reaction. Leucocytes,
antigens and sera were mixed as shown
in Table II. It can be seen that serum
from patient A.C. (melanoma) consistently
blocked the reaction between her own
cells and melanoma antigen. Further-
more, the same serum blockedina system
which employed allogeneic cells from
another patient with the same type of
tumour. Serum from a patient with
carcinoma ofbreast blocked the reactivity
of her own leucocytes.
The need for specificity controls is
ideally met by the use of a " criss-cross "
experimental design employing leucocytes,
antigen and serum from 2 unrelated
tumours, as in Table III. Here the
melanoma antigen (but not colonic carci-
noma antigen) inhibited leucocytes from
a melanoma patient but there was pre-
cisely the reverse activity with leucocytes
from colonic carcinoma. Melanoma serum
(but not colonic carcinoma serum) blocked
in the melanoma system, and the serum
activities were reversed in the tests with
leucocytes from colonic carcinoma.
DISCUSSION
The general characteristics of the LAI
test have been fully described previously
forexperimentaltumoursofmice(Halliday
et at., 1973). Application of the test to
human tumours has now been accom-
plished successfully and most of the
previous findings confirmed. Thus, both
human patients and tumour bearing mice
have leucocytes reactive with a soluble
tumour antigen; this property is detect-
TABLE II.-Effect ofAppropriate Tumour Serum on LAI
Leucocytes
Melanoma (A.C.)
Me
Me
Me
Me
Me
Cai
Cai
Cai
% Adherence*
Antigen Serum (Mean ± s.e.)
Normal f65 2 ± 2 2
- '~~~~~~65-2 ± 2-8
Comment
32.9 2 20 Cells active; ,lanoma (A.C.) Ml Normal 35-8 ±-0 P < 0-001
al65 0 ± 2-4 Serum blocking; flanoma (A.C.) M1 Melanoma (A.C.) -62-8 i 26 P < 0 001
Cells active;
lanoma (M.G.) Normal 52 9 ± 29 P < 0.001
)lanoma (M.G.) Ml Normal 35.5 i 21 Serum partially
,lanoma (M.G.) Ml Melanoma (A.C.) 43.7 ± 3.3 blocking;
P < 0 05
rcinoma of breast (O.K.) Normal 68 8 i 2 2 Cells active;
rcinoma of breast (O.K.) B2 Normal 34.7 i 2-3 P < 0 001
rcinoma of breast (O.K.) B2 Carcinoma of breast 74 4 ± 20 Serum blocking;
(O.K.) P < 0-001
* Bracketed results obtained with the same antigen and serum, but freshleucocytes, on two differentdays
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TABLE III. Specificity of LAI and Blocking tith Two Different Tumnours
Leucocytes
Melanoma (W.D.)
Melanoma (W.D.)
Melanoma (W.D.)
Melanoma (W.D.)
Carcinoma of colon (J.T.)
Carcinoma of colon (J.T.)
Carcinoma of colon (J.T.)
Carcinoma of colon (J.T.)
Antigen Serum
C3 Normal
All Normal
AlI M Aelanoma (W.D.)
MII Carcinoma of colon
(J.T.)
AlI Normal
C3 Normal
C3 Carcinoma of coloni
(J .T.)
C3 Melanoma (W.D.)
0 Adherence
(Mean ± s.e.)
65 9 : 3-1
41 6 - 2 2
74.9 1 I
496 6 1 7
67-2 29
328 8+ 1 8
58 3 2 25
38-2 ± 25-
Commenit
Cells active;
P < 0001
Serum blocking;
P < 0001
Blocking specific
Cells active;
P < 0O001
Seruim blockinig;
P < 0001
Blocking specific
able by a rapid test which is within the
capabilities of any laboratory. Further-
more, specific blocking is demonstrated
easily with serum. These immunological
reactions of CMI and BF were detected
consistently in a small series of patients.
An important difference between the
behaviour of the human tumours studied
so far by the LAI test, compared with
murine tumours, is in the tumour speci-
ficity of the reaction. Methylcholan-
threne induced tumours in CBA mice
appeared to have quite distinctive anti-
gens, with no cross-reactivity between
individual tumours (Halliday et al., 1973).
The human tumours cross-reacted within
each tumour type, as reported here, so
that leucocytesfrom onemelanoma patient
reacted with antigen from any other (but
not with antigen from colon carcinoma),
and vice versa. Cross-reactivity or " group
specificity " extended also to the blocking
phenomenon, so that completely allo-
geneic mixtures (leucocytes, tumour ex-
tract and serum, all from different sources)
could be used to detect the desired
activity. This is very convenient for a
practical test since a stored extract can
be used to detect CMI in a patient's
leucocytes (if his own tumour is not
available or even before clinical diagnosis)
and blocking can be looked for with only
a serum sample (provided a tumour
extract and another patient's active cells
are available).
Common antigens in tumours of the
same type or origin have been described
by several investigators. Thus, melano-
mata were reported to possess common
tumour associated antigens (Morton et al.,
1968; Hellstr6m et al., 1971a; Nairn et al.,
1972; Hellstrom and Hellstr6m, 1973a),
although the use of different techniques
has led to the discovery of individually
unique antigens also (Lewis et al., 1969;
Nairn et al., 1972). Analogous observa-
tions have been made with many other
types of tumours (Hellstr6m et al., 1971a).
The obvious applications of tests for
CMI and BF in the specific diagnosis of
cancer and in evaluating the results of
treatment have been emphasized previ-
ously (Hellstrom and Hellstr6m, 1973b),
as has the need for simple techniques
permitting routine or sequential assays
(Hellstr6m et al., 1973; Heppner et al.,
1973). The LAI test appears to be
capable of satisfying this need and to give
results remarkably similar to those from
lymphocyte cytotoxicity tests. It could
perhaps be made less tedious by use of an
electronic cell counter (Lampert and
Dietmair, 1973).
We stress the usefulness of the LAI
technique in obtaining rapid results with
a minimum of equipment. In contrast,
other laboratory methods, as listed above,
for detecting anti-tumour immunity are
slower, more laborious or require elaborate
instrumentation.
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